Robrecht Froyman, DVM, most recently served as Manager, Discovery Anti-infectives, at Bayer HealthCare with stationary at the headquarters of Bayer Animal Health from January 1991 to July 2014. Dr. Froyman was responsible to evaluate new antimicrobial compounds/products from R&D and regulatory perspectives. He also was the key scientist of the R&D antimicrobial drug evaluation team, assessed technical profiles, and conducted proof-of-concept trials for veterinary products. Dr. Froyman also aligned with preclinical (toxicology, pharmacokinetics) and chemistry (in silico) for trials prior to phase1, provided assistance and guidance to the drug scouting team within new business development, and attended appropriate seminars and congresses. In the past he provided key contributions in clinical development (worldwide) and regulatory affairs (US, EU) leading to the approval of Bayer's highest selling, veterinary antimicrobial compound. Dr. Froyman has skills and experience in: Poultry diseases (particularly chicken and turkey coccidiosis); Food safety and antimicrobial resistance issues (e.g. salmonellosis, campylobacteriosis); Drug discovery/scouting (including basic medicinal chemistry) as well as research (including preclinical POC and toxicity testing) and development (including pharmacokinetics) of veterinary antimicrobial compounds with focus on bovine mastitis (including immunobiology issues) and avian/porcine/bovine respiratory disease. Finally Dr. Froyman is an experienced medical writer (author or co-author of 51 peer-reviewed papers and 73 scientific congress contributions/posters).